Prosecution Insights
Last updated: April 19, 2026

Dragonfly Therapeutics Inc.

5 pending office actions

Portfolio Summary

5
Total Pending OAs
3
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18108961 PROTEINS BINDING NKG2D, CD16 AND NECTIN4 BRISTOL, LYNN ANNE 1643 Final Rejection Feb 13, 2023
18166769 PHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND EGFR, NKG2D, AND CD16 CHASE, CAROL ANN 1646 Non-Final OA Feb 09, 2023
17769160 PROTEINS BINDING NKG2D, CD16 AND FLT3 GUSTILO, ESTELLA M 1646 Final Rejection Apr 14, 2022
17058335 MULTI-SPECIFIC BINDING PROTEINS AND IMPROVEMENTS THEREON YAO, LEI 1642 Final Rejection Nov 24, 2020
16615261 PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN JOHANSEN, PETER N. 1644 Non-Final OA Nov 20, 2019

Managing Dragonfly Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month